There are 807 resources available
388P - Capmatinib in Chinese adults with EGFR wt, ALK rearrangement negative (ALK-R−), MET exon 14 skipping mutation (METex14), advanced NSCLC: Results from the phase II GEOMETRY-C study
Presenter: Yi-Long Wu
Session: Poster viewing 05.
389P - Updated efficacy and safety of pralsetinib in Chinese patients with advanced RET fusion+ non-small cell lung cancer
Presenter: Zhou Qing
Session: Poster viewing 05.
390P - Entrectinib in Japanese patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours
Presenter: Haruyasu Murakami
Session: Poster viewing 05.
391P - Demographics, treatment patterns and clinical outcomes in ROS1-positive non-small cell lung cancer: A referral tertiary cancer centre experience from a low-middle income country
Presenter: Goutam Panda
Session: Poster viewing 05.
392P - A phase II study of SAF-189s in patients with advanced ROS1 fusion-positive non-small cell lung cancer
Presenter: Jinji Yang
Session: Poster viewing 05.
394P - Research of the algorithm for rare driver genes in non-small cell lung cancer using pathological images and artificial intelligence
Presenter: Kiyotaka Yoh
Session: Poster viewing 05.
395P - Molecular landscape of Indian NSCLC: Is NGS the answer?
Presenter: Ullas Batra
Session: Poster viewing 05.
396P - Mutational profiling by next generation sequencing in patients with metastatic non-small cell lung carcinoma
Presenter: Hitesh Deka
Session: Poster viewing 05.
397TiP - Phase III LUNAR study: Tumor treating fields (TTFields) with standard of care for the treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure
Presenter: Li Zhang
Session: Poster viewing 05.
398TiP - MARIPOSA-2: Randomized phase III study of amivantamab + lazertinib + chemotherapy vs chemotherapy alone in EGFR-mutant NSCLC after osimertinib failure
Presenter: Jie Wang
Session: Poster viewing 05.